ArticlePulmonary therapy2025

Clinically Important Improvements and Disease Stability with Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy in the ELLITHE Trial: A Post Hoc Responder Analysis.

Kai-Michael Beeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.